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1Pharmacokinetics and pharmacodynamics 
of the nucleoside sparing dual regimen 
containing rilpivirine plus darunavir/ritonavir 
in treatment-naïve HIV-1-infected individuals
Akil Jackson1,2  , Laura Else2, Christopher Higgs1, Zeenat Karolia1,  
Saye Khoo2, David Back2, Emma Devitt1, Anton Pozniak1, Marta Boffito1,3
1St Stephen’s Centre, Chelsea and Westminster Hospital, London, UK, 2Department of Clinical and Molecular 
Pharmacology, University of Liverpool, Liverpool, UK, 3Department of Medicine, Imperial College, London, UK
Background: We aimed at investigating the antiviral activity and the pharmacokinetics of the dual antiretroviral 
(ARV) combination of rilpivirine plus darunavir/ritonavir 25/800/100  mg once-daily in naïve HIV-1-infected 
individuals (NHII) with different baseline viral loads.
Settings: Pharmacokinetic/pharmacodynamics study in ARV-naïve HIV-infected individuals.
Methods: The primary endpoint was the number of NHII with HIV-RNA < 40 copies/mL at week 48. Secondary 
endpoints included rilpivirine/darunavir/ritonavir pharmacokinetics, HIV-RNA decay, and changes in ECG QT 
interval.
Results: Thirty-six individuals were enrolled, 18 with a baseline viral load < 100,000 copies/mL (group A) and 18 
with a baseline viral load > 100,000 copies/mL (group B). All but 1 (HIV-RNA = 63 copies/mL) subjects achieved 
viral load < 50 copies/mL by week 36, and all at week 48. Median (range) HIV-RNA reduction (Log10 copies/
mL) was 1.3 (0.6–1.9) over the first week, with no differences between groups A and B. Geometric mean and 
95%CI rilpivirine Cmax, Ctrough, AUC were 183 (165–239), 114 (104–109) ng/mL, 2966 (2704–3820) ng h/mL. No 
QTcF interval changes were recorded.
Conclusions: rilpivirine/darunavir/ritonavir could be efficacious, with limited short-term toxicity in ARV-naïve 
patients. Although rilpivirine was co-administered with ritonavir, its exposure was within ranges measured during 
phase III trials.
Keywords: Dual antiretroviral therapy, Pharmacokinetics, HIV antiviral pharmacology, Rilpivirine, Darunavir
Background
Triple drug antiretroviral combination therapy (cART, 
containing two nucleoside analogs, NRTIs, and a third 
agent) is recommended by international guidelines for the 
treatment of HIV infection.1 However, drug-sparing strat-
egies, such as dual therapies, have been explored lately in 
numerous studies aiming at improving tolerability, adher-
ence, and reducing toxicity and cost.2–5
Additionally, (i) the possible transmission of virus 
already containing resistance mutations, such that patients 
may have a viral genotype with less than optimal suscep-
tibility to the commonly used NRTIs1 (ii) the low genetic 
barrier of certain NRTIs like lamivudine (3TC) and the 
likelihood of some patients to harbor resistance to this or 
other NRTIs if they have a history of poor adherence,6 
and (iii) the rapidly increasing use of tenofovir disoproxil 
fumarate (TDF)/emtricitabine (FTC)-based pre-exposure 
prophylaxis (PrEP) for HIV that may increase the devel-
opment of resistance in individuals who seroconvert on 
PrEP,7 are other important factors to consider when inves-
tigating optimal alternative cART.
Rilpivirine, is a HIV non-nucleoside reverse transcriptase 
inhibitor (NNRTI) approved in Europe and the USA for 
treatment of therapy-naïve HIV-1 infected adult patients 
(with a viral load </= 100,000 copies/mL) in combination 
with other agents.8,9 It primarily undergoes oxidative metab-
olism mediated by the cytochrome P450 (CYP) 3A system, 
therefore drugs that induce or inhibit CYP3A may affect its 
clearance.10 The recommended dose of rilpivirine is 25 mg 
given once-daily, taken with a meal of at least 390 kcal.8
Darunavir, is a member of the protease inhibitor class. 
In treatment-naïve patients, the recommended  darunavir 
dose is 800 mg with ritonavir (a potent inhibitor of 
CYP3A4) 100 mg once-daily taken with food.11
A phase I study investigating the drug interaction 
between rilpivirine dosed at 150 mg once-daily and Correspondence to: Marta Boffito, St. Stephen’s Centre – Chelsea and Westminster Hospital, 369 Fulham Road, London, SW10 9NH, UK. Email: 
marta.boffito@nhs.net
© 2017 Informa UK Limited, trading as Taylor & Francis Group
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darunavir/ritonavir in HIV-negative healthy volunteers 
showed an increase in rilpivirine pharmacokinetic param-
eters ranging between 80 and 180% with no changes in 
darunavir or ritonavir concentrations.12
However, data in adult antiretroviral-naïve patients 
living with HIV (PLWH) on the currently approved 
rilpivirine dose of 25 mg once-daily are lacking. Yet, a 
combination of rilpivirine and ritonavir-boosted darun-
avir could potentially form a once-daily NRTI-sparing 
treatment, as shown in a switch study by Maggiolo et 
al.13 and in a study in adolescents by Foca et al.14 Hence, 
this study investigated the antiviral activity, steady-state 
pharmacokinetics and safety of rilpivirine plus darunavir/
ritonavir in therapy-naïve HIV-infected adults.
Methods
Participants
Written informed consent was obtained from PLWH 
(between December 2012 and February 2014), aged 18 
to 65 years old, naïve to cART with a VL > 1000 copies/
mL and a CD4 count > 50 cells/mm3. As this was a pilot 
investigational study (where 15–20 patients per group 
were assumed to draw for relevant conclusions because of 
the intense pharmacokinetic/pharmacodynamics assess-
ments), patients with CD4 counts < 200 cells/mm3 and 
viral loads above 100,000 copies/mL (see below) were 
included despite treatment guidelines recommendations.1 
Participants were excluded if they had significant acute or 
chronic psychiatric/medical illnesses that could have inter-
fered with the ability of taking part in the study, anomalies 
and risk factors for QTc prolongation (QTc interval was 
calculated with the Fridericia’s equation, QTcF) or clinical 
laboratory determinations; positive screens for hepatitis 
B/C; baseline transmitted resistance compromising rilpi-
virine (K101E, K101P, E138A, E138G, E138K, E138R, 
E138Q, V179L, Y181C, Y181I, Y181V, H221Y, F227C, 
M230I, M230L) and darunavir (V11I, V32I, L33F, I47V, 
I50V, I54M, I54L, T74P, L76V, I84V, L89V) efficacy; use 
of other drugs known to interact with the study drugs (this 
was also checked throughout the 48-week study duration 
period).
Study design
This was a single-arm, open-label study approved by 
the City and East Research Ethics Committee and 
the Medicines and Healthcare products Regulatory 
Agency (MHRA), UK (EUdraCT – 2012-002663-10; 
Clinicaltrials.gov NCT01736761). Because of the pilot 
nature of the study, a sample size calculation was not 
performed.
Following recruitment of the first 10 participants with 
baseline viral loads below 100,000 copies/mL (group A), 
a protocol steering committee convened to review viral 
load responses over the first four weeks of therapy and 
to advise on whether to proceed with recruitment of par-
ticipants with baseline viral loads above 100,000 copies/
mL (group B).
After successful screening, participants were admin-
istered rilpivirine 25 mg plus darunavir/ritonavir 
800/100 mg once-daily, and given weekly appointments 
until week 4 for drug concentration measurement (trough 
concentration, Ctrough), HIV-RNA testing and resting ECG 
monitoring. At week 4, they were admitted to the research 
unit for 24 h pharmacokinetic sampling, blood was taken 
pre-dose, 1, 2, 4, 6, 8, 12, and 24 h post-dose. Follow-up 
appointments for safety laboratory test, viral load meas-
urement and ECG monitoring were at weeks 6, 8, 10, 12, 
24, 36, and 48 post-cART initiation.
On the pharmacokinetic day, the study medication was 
taken with a standardized breakfast (534 kcal) and 240 mL 
of water. Compliance with study drug administration was 
assessed by pill counting by the study staff throughout 
the study period.
Bioanalysis (drug plasma concentration 
measurement)
Blood samples were collected for the measurement of 
rilpivirine, darunavir, ritonavir concentrations into lith-
ium heparin-containing blood tubes (6 mL) at each time 
point, protected from light and immediately inverted 
several times and then kept on ice or refrigerated until 
centrifugation. Within 30 min of blood collection, each 
blood sample was centrifuged for 10 min at 1200 g at 
4 °C. Plasma was then aliquoted equally into three 2.0 mL 
tubes (light protected) and stored at –20 °C. Samples were 
shipped on dry ice to the Liverpool Bioanalytical Facility 
for analysis.
Plasma drug concentrations were determined using 
protein precipitation of analyte and stable isotope labe-
led internal standard using validated high-pressure liquid 
chromatography tandem mass spectrometry methods, as 
previously described.15,16 The assay was validated over 
a calibration range of 15–15000 ng/mL (darunavir), 
5–5000 ng/mL (ritonavir), and 0.5–400 ng/mL (rilpivir-
ine). The accuracy (percentage bias) and precision (% 
coefficient of variation) were less than 15%.
Data analysis
All HIV-RNA for the studied subjects were transformed 
to the Log10 scale and a linear mixed model fitted, with 
the trend estimated using a cubic spline.
The calculated pharmacokinetic parameters for 
 rilpivirine, darunavir, and ritonavir were the plasma con-
centration measured 24 h after the observed dose (Ctrough), 
the maximum observed plasma concentration (Cmax) and 
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24 h (AUC0-24). All pharmacokinetic parameters were cal-
culated using actual blood sampling time and non-com-
partmental modeling techniques (WinNonlin Phoenix, 
version 6.1; Pharsight Corp., Mountain View, CA). 
Descriptive statistics, including geometric mean (GM) 
and 95% confidence intervals (95% CI) were calculated 
for all pharmacokinetic parameters. Inter individual vari-
ability in drug pharmacokinetic parameters was expressed 
as a percentage coefficient of variation [CV, (standard 
deviation/mean) × 100].
Pearson correlation was used to investigate the pres-
ence of a relationship between rilpivirine exposure and 
QTc interval four weeks after drug initiation.
Results
Fifty-two PLWH and naïve to cART were screened for 
the study and 37 were enrolled. One subject withdrew for 
personal reasons, therefore 36 completed the study (Table 
1). Thirty-five were males and 33 were Caucasian (two 
Indians and one Pakistani); median (range) age was 35 
(21–58) years. Baseline median (range) CD4 count was 
388 (170–1375) cells/mm3. Pre-cART resistance testing 
showed that no patient had any resistance to NNRTIs or 
protease inhibitors, while four had baseline resistance to 
NRTIs expressed as a single thymidine analog mutation 
(TAM).
Viral load dynamics
Eighteen subjects had a baseline viral load below 100,000 
copies/mL (group A) and 18 with a baseline viral load 
above 100,000 copies/mL (group B) at screening (Table 
2). Viral load decay curve is illustrated in Figure 1. All 
but one (viral load = 63 copies/mL at week 36, baseline 
36,769 copies/mL, baseline CD4 count 345 cells/mm3) 
study subjects achieved viral load < 50 copies/mL by 
week 36 and all by week 48 (Table 1). Overall median 
(range) viral load reduction (Log10 copies/mL) was 1.3 
(0.6–1.9) over the first week of treatment, with no major 
differences between group A and B (Table 2).
Pharmacokinetics
GM plasma concentration vs. time curves for rilpivirine, 
darunavir, and ritonavir are shown in Figure 2 and their 
pharmacokinetic parameters summarized in Table 3.
Although approximately 45% higher, rilpivirine AUC 
measured in this study was within the range of those 
reported from Phase III pharmacokinetic substudies that 
showed an inter-individual variability in rilpivirine expo-
sure of 45%.10
All subjects had darunavir Ctrough values above the pro-
tein binding adjusted IC50 of 550 ng/mL, and the daruna-
vir pharmacokinetic parameters measured were similar to 
those reported from Phase III studies (Table 3).11
Safety and tolerability
Study drugs were well tolerated with no subjects dis-
continuing rilpivirine and darunavir/ritonavir because of 
drug-related toxicity.
Three serious adverse events were recorded during the 
study, none of which were deemed by the investigator to 
be related to study medication: (i) admission to hospi-
tal for treatment of prostatitis complicated by peri-ure-
thral abscess; (ii) overnight admission to hospital to treat 
dehydration and confusion caused by recreational drug 
intoxication; (iii) laparotomy and bowel resection with 
temporary stoma to repair rectal trauma.
Table 1 Baseline demographic and clinical characteristics of the 36 subjects who completed the study
*Non-B subtypes were AG, D, C, and AE.
Note: N = number, MSM = men who have sex with men, BMI = body mass index
Group A (n = 18) Group B (n = 18) All subjects (n = 36)
Gender (male:female) 17:1 18:0 35:1
Age (years) 36 35 34
Median (range) (21–58) (21–54) (21–58)
Mode of HIV transmission
 MSM 16 17 33
 Heterosexual 1 – 1
Unknown 1 1 2
HIV-RNA (copies/mL) 91,999 24,403 215,120
Median (range) (807–5,595,624) (807–78,113) (105,885–5,595,624)
HIV Subtype
 B (N) 15 13 28
 Non-B (N) 3 5 8*
CD4 count (cells/mm3) 388 450 370
Median (range) (170–1375) (204–1375) (170–787)
N with CD4 count < 200 1 None 1
QTc m/sec 360 358 360
Median (range) (308–404) (308–404) (324–404)
BMI (kg/m2) 23 22 23





























HIV Clinical Trials  2017  4
Jackson et al. Rilpivirine/darunavir/ritonavir PK/PD
no relationship between riplvirine Cmax and QTcF inter-
val were observed 9p = 0.26). No laboratory parameter 
changes higher than Grade 2 were measured.
Discussion
In this pharmacokinetic/pharmacodynamic study in HIV-
1-infected treatment-naive participants, the NRTI-free 
There were no other adverse events higher than 
Grade 2 of severity. Two patients experienced a transient 
self-limiting generalized rash (without mucosal involve-
ment) following cART initiation, which resolved with 
continued dosing.
No significant change from baseline, no QTcF interval 
greater than 450 ms were recorded during the study and 
Table 2 Viral load (VL) decay in the 36 subjects who completed the study, and in group A (VL < 100,000 copies/mL) and group 
B (VL > 100,000 copies/mL) over the study period
Visit time points
Overall n = 36
Subgroup of HIV RNA at baseline
A = Under 100,000 B = At least 100,000
n = 18 n = 18
Mean Standard deviation Mean Standard deviation Mean Standard deviation
Viral load at baseline 376,746.8 1,026,153.2 28,621.7 21,687.4 724,871.8 1,382,320.9
(copies/ml) n = 36 n = 18 n = 18
Viral load at week 1 9663.3 13,423.7 1630.8 2001.7 17,695.8 15,177.3
(copies/ml) n = 36 n = 18 n = 18
Viral load at week 2 4177.3 8177.9 864.0 1513.5 7490.6 10,597.9
(copies/ml) n = 34 n = 17 n = 17
Viral load at week 3 2915.7 4650.8 419.6 415.0 5273.1 5566.3
(copies/ml) n = 35 n = 17 n = 18
Viral load at week 4 2242.1 3416.2 349.7 215.4 3911.8 4031.3
(copies/ml) n = 32 n = 15 n = 17
Viral load at week 6 1200.4 1690.7 205.5 184.3 1974.2 1933.2
(copies/ml) n = 32 n = 14 n = 18
Viral load at week 8 752.9 951.2 236.9 228.6 1096.8 1093.8
(copies/ml) n = 30 n = 12 n = 18
Viral load at week 10 500.4 541.4 165.8 158.3 667.7 589.6
(copies/ml) n = 27 n = 9 n = 18
Viral load at week 12 292.6 347.5 87.8 42.4 413.1 391.8
(copies/ml) n = 27 n = 10 n = 17
Viral load at week 24 68.6 25.1 77.0 NA 67.4 26.9
(copies/ml) n = 8 n = 1 n = 7
Viral load at week 36 53.5 13.4 63.0 <50
(copies/ml) n = 2 n = 1 – –
Viral load at week 48 <50 – <50 – <50
(copies/ml)
Figure 1 Geometric mean viral load decay over 24 weeks of rilpivirine/darunavir/ritonavir treatment in Group A (straight line) 
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load of 63 copies/mL, by week 36). A secondary objective 
was to investigate whether baseline viral load (higher or 
lower than 100, 000 copies/mL) would influence virologic 
combination containing rilpivirine and darunavir/ritona-
vir led to achievement of an undetectable viral load in all 
subjects at week 48 (and in all but one who had a viral 
(A)
(B)
Figure 2 Geometric mean (GM, solid line) and 95% confidence interval (95% CI, dotted lines) plasma concentrations of 
rilpivirine (A), and darunavir/ritonavir (B). Y-axes are illustrated as logarithmic scales, and straight lines indicate: (A) rilpivirine 
concentration associated with a 90% reduction in viral replication (inhibitory concentration, IC90) of 12 ng/mL and (B) solid 
line darunavir half-maximal effective concentration (EC50) (resistant, protein adjusted = 550 ng/mL) and dotted line darunavir 
90% of maximal EC (EC90) (WT, protein adjusted = 200 ng/mL)
Table 3 Rilpivirine (RPV), darunavir (DRV) and ritonavir (RTV) pharmacokinetic (PK) parameters at steady state in 36 patients 
living with HIV (PLWH) expressed as geometric mean (GM) and 95% confidence intervals (95%CI). Rilpivirine concentration 
associated with a 90% reduction in viral replication (inhibitory concentration, IC90) for wild type virus and protein binding 
adjusted is 12 ng/mL and darunavir 90% of maximal EC (EC90) for wild-type virus and protein binding adjusted is 200 ng/mL
PK parameter RPV DRV RTV
N = 36 GM (95% CI)
AUC0–24 h 3036 82,598 4455
ng h/mL (2876–3969) (76,508–113,143) (4098–6475)
CV% 49 59 68
Cmax 188 8381 503
(ng/mL) (175–248) (7802–11,279) (463–845)
CV% 53 56 90
Ctrough 116 1728 42
(ng/mL) (106–171) (1661–2669) (38–60)
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by NEAT001 that showed that the dual regimen contain-
ing raltegravir plus darunavir/ritonavir did not achieve 
non-inferiority in individuals with high baseline viral 
loads and low CD4 counts.2,17 Furthermore, the efficacy 
of RPV/DRV/r in maintaining an undetectable viral load 
in suppressed patients as a switch strategy and in adoles-
cents has also been confirmed.13,14
Interest in reducing the number of drugs in a standard 
antiretroviral regimens is growing and different inno-
vative boosted protease inhibitor-free combinations are 
being studied with drugs with a high genetic barrier like 
dolutegravir, in combination with a NRTI (e.g. lamivu-
dine, 3TC)4 or an NNRTI (e.g. rilpivirine).5 The outcome 
of these studies is important because new dual combina-
tions may limit short- and long-term antiretroviral drugs 
toxic effects. Importantly, however, dual regimens need to 
be carefully selected and to date large randomized clinical 
trial data on dual therapy are available only for boosted 
protease inhibitor-containing combinations.3,4,20
In conclusion, our study has demonstrated that the 
combination of rilpivirine and darunavir/ritonavir could 
be efficacious, with limited short-term toxicity in ARV-
naïve patients. Therefore, it is potentially useful as an 
alternative strategy in patients for whom standard cART 
is not an option due to resistance or toxicity.
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response and no differences in viral load decrease or 
achievement of an undetectable viral load were observed 
between patients with a baseline viral load above and 
below 100,000 copies/mL.
Rilpivirine exposure was slightly increased by ritona-
vir co-administration via CYP3A4 inhibition; however, 
its AUC was still within the range observed in historical 
controls.9,10 Importantly, no changes in ECG QTcF were 
seen during the study. The study drugs were well tolerated 
with no drug-related adverse events or laboratory param-
eters higher than Grade 2.
While an association between efficacy and baseline 
viral load has been demonstrated with other cARTs con-
taining two or three active drugs,2,17,18 this small but inten-
sive study showed that rilpivirine plus darunavir/ritonavir 
is efficacious independently of baseline viral load. A poten-
tial explanation of this finding could be (i) the slightly 
higher concentrations that were measured for rilpivirine 
in the presence of darunavir/ritonavir, however this would 
be difficult to prove as pharmacokinetic/pharmacodynamic 
data from Phase III clinical trials with higher rilpivirine 
dose are unavailable; or (ii) the fact that being this a phar-
macokinetic/pharmacodynamic study, participants were 
followed closely and adherence monitored frequently, 
especially during the first four weeks of treatment.
Although rilpivirine can prolong the QTc interval in a 
dose-dependent manner8 and increases in its concentra-
tions were expected because of ritonavir co-administra-
tion and CYP3A4 inhibition, ECG recordings throughout 
the study were available and showed no change in QTcF 
from baseline and no correlation between QTc change 
and rilpivirine Cmax.
Dual antiretroviral treatments containing a boosted pro-
tease inhibitor-based therapy, (e.g. a boosted protease inhib-
itor plus one agent from another class) is not the preferred 
strategy recommended by most recent guidelines. However, 
over the past 15 years numerous studies have been published 
showing how dual antiretroviral therapies may be benefi-
cial in clinical practice. Importantly, a recent meta-analysis 
showed minor differences in terms of virological efficacy 
when comparing dual to triple cART.19 Furthermore, it was 
observed that although a similar risk of serious adverse 
events in patients on dual and triple therapies, the former 
had a lower risk of adverse events leading to discontinua-
tion, suggesting that dual therapies may be better tolerated.19
Interpretation of these data should take into account its 
single-arm design, the pilot nature of the study, and the 
small number of patients studied. A larger randomized 
trial comparing rilpivirine plus darunavir/ritonavir to 
standard of care is warranted to draw definite conclusions. 
However, interestingly in the past, single-arm Phase IIb 
trials have predicted more definitive findings from Phase 
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